BIOS Builders Interview with Mark Chao, Co-founder & CEO at TenSixteen Bio

Foresite Labs’ new $173M fund to bankroll fewer startups but ‘big ideas’ fueled by data

Foresite Capital Launches $173M Fund to Support Incubated Companies

TenSixteen Bio Plumbs Somatic Mosaicism for Source of Multiple Diseases

TenSixteen targets dynamic genome to find driver mutations, catch cancer earlier

Foresite and GV pour $40M into startup’s move to CHIP into new disease biology

With Forty Seven co-founder at the helm, new biotech spinout launches to target mutations potentially linked to numerous diseases

TenSixteen Bio Launches With $40M Series A To Advance A New Approach To Disease Detection And Treatment

Foresite Labs Hatches Big-Data-Driven Companies Destined to Shake up Healthcare

Seven Biopharma Trends to Watch in 2022